TLDR:
- XGEN Venture announced its first fund, XGEN Venture Life Science Fund, with €160 million in commitments.
- The fund will invest in up to 15 companies focusing on new therapeutics, medical devices, diagnostics, and digital health solutions.
XGEN Venture recently closed its Life Science Fund with €160 million in commitments. The fund aims to work with scientists and entrepreneurs to create and invest in up to 15 companies that deliver solutions to patients in the form of new therapeutics, medical devices, diagnostics, and digital health solutions. A significant portion of the company’s investments will be in technologies originating from Italian research institutes. The fund, launched in December 2022, is still fundraising towards a final target of €200 million and has received support from institutional investors such as EIF, CDP VC, UniCredit, and more. XGEN has already invested in five companies, including those focused on breakthrough cancer therapies, cardiovascular interventional procedures, drug discovery, and gene therapy for rare diseases. The fund also emphasizes best ESG practices within the meaning of SFDR art.8. XGEN’s founders and managing partners have a strong background in life science venture capital investments, having successfully invested over €200 million in early-stage startups. The team includes venture partners with extensive operational backgrounds in the life sciences industry, and all team members have invested in the fund. The fund’s closing quote emphasizes the team’s commitment to continue building and growing companies to address serious health conditions.
